New facets of the multiorgan effectiveness of dipeptidyl peptidase-4 inhibitors
https://doi.org/10.62751/2713-0177-2025-6-3-11
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of sugar-lowering drugs characterized by a favorable safety profile and a neutral effect on body weight. They are characterized by low incidence of side effects and good tolerability, even in patients with endstage chronic kidney disease. Preclinical and clinical studies have shown that these drugs have a wide range of pleiotropic effects on the cardiovascular and central nervous systems, and other organs. One key mechanism explaining the cardioprotective properties of DPP-4 inhibitors is their anti-inflammatory effect. The use of these drugs has been associated with decreased systemic markers of inflammation such as C-reactive protein and pro-inflammatory cytokines, potentially reducing the risk of atherosclerosis and its complications. In addition, DPP-4 inhibitors improve endothelial function by increasing the bioavailability of nitric oxide and reducing the adhesion of leukocytes to the vascular wall, which contributes to vasodilation and reduces the likelihood of vascular complications. This review provides basic information about DPP-4 inhibitors, examines the clinical prospects for its use, and substantiates the benefits of combination therapy as well as the main pleiotropic effects on the cardiovascular system and brain.
About the Authors
T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatyana Yu. Demidova – D. Sci. (Med.), Prof., Head of the Department of endocrinology, Institute of Clinical Medicine
Moscow
M. Ya. Izmailova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Maryam Ya. Izmailova – assistant at the Department of endocrinology, Institute of Clinical Medicine
Moscow
References
1. Cook AK, Behrend E. SGLT2 inhibitor use in the management of feline diabetes mellitus. J Vet Pharmacol Ther. 2025;48 Suppl 1(Suppl 1):19–30. doi: 10.1111/jvp.13466.
2. Duncan BB, Magliano DJ, Boyko EJ. IDF diabetes atlas 11th edition 2025: Global prevalence and projections for 2050. Nephrol Dial Transplant. 2025:gfaf177. doi: 10.1093/ndt/gfaf177. Online ahead of print.
3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. 12-й выпуск. М. 2025.
4. Laiteerapong N, Ham SA, Gao Y, Moff HH, Liu JY, Huang ES, Karter AJ. The legacy eff in type 2 diabetes: Impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–26. doi: 10.2337/dc17-1144.
5. Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–29. doi: 10.1016/S0140-6736(19)32131-2.
6. Cheung JTK, Yang A, Wu H, Lau ESH, Lui J, Kong APS et al. Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability. Diabetes Obes Metab. 2024;26(8):3339–51. doi: 10.1111/dom.15662.
7. Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB. The time is right for a new classification system for diabetes: Rationale and implications of the β-cell-centric Classification Schema. Diabetes Care. 2016;39(2):179–86. doi: 10.2337/dc15-1585.
8. Bluher M, Malhotra A, Bader G. Beta-cell function in treatment-naïve patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials. Diabetes Obes Metab. 2023;25(5):1403–7. doi: 10.1111/dom.14969.
9. Cheung JTK, Yang A, Wu H, Lau ESH, Lui J, Kong APS et al. Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability. Diabetes Obes Metab. 2024;26(8):3339–51. doi: 10.1111/dom.15662.
10. Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: Exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37(1):e11–e12. doi: 10.2337/dc13-1523.
11. Lin T, Cai Y, Tang L, Lian Y, Liu M, Liu C. Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: A systematic review and meta-analysis. J Diabetes Investig. 2022;13(9):1506–19. doi: 10.1111/jdi.13814.
12. American Diabetes Association. Standards of medical care in diabetes – 2025. Diabetes Care. 2025;48(Suppl 1):S1–344.
13. Makrilakis K. The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: When to select, what to expect. Int J Environ Res Public Health. 2019;16(15):2720. doi: 10.3390/ijerph16152720.4.
14. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–20. doi: 10.1111/dom.12000.
15. Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N et al.; Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A randomized controlled trial. Diabetes Care. 2016;39(3):455–64. doi: 10.2337/dc15-2145. Erratum in: Diabetes Care. 2017;40(6):808. doi: 10.2337dc17-er06a.
16. Wang J, Wu HY, Chien KL. Cardioprotective eff of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes. Diabetes Metab. 2022;48(3):101299. doi: 10.1016/j.diabet.2021.101299.
17. Wicinski M, Gorski K, Wodkiewicz E, Walczak M, Nowaczewska M, Malinowski B. Vasculoprotective effects of vildagliptin. Focus on atherogenesis. Int J Mol Sci. 2020;21(7):2275. doi: 10.3390/ijms21072275.
18. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hypertens. 2016;34(2):167–75. doi: 10.1097/HJH.0000000000000782.
19. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4(6):640–50. doi: 10.1111/jdi.12087.
20. Celis-Morales S, Franzen AM, Svensson N, Sattar S. Gudbjornsdottir. EASD. 56th Annual Meeting. September 2020.
21. Jiang X, Li J, Yao X, Ding H, Gu A, Zhou Z. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: A narrative review. Front Pharmacol. 2024;15:1361651. doi: 10.3389/fphar.2024.1361651.
22. El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA. Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative-infl y-apoptotic pathway. Life Sci. 2015;126:81–86. doi: 10.1016/j.lfs.2015.01.030.
23. Hung YW, Wang Y, Lee SL. DPP-4 inhibitor reduces striatal microglial deramification after sensorimotor cortex injury induced by external force impact. FASEB J. 2020;34(5):6950–64. doi: 10.1096/fj.201902818R.
24. Jiang X, Li J, Yao X, Ding H, Gu A, Zhou Z. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: A narrative review. Front Pharmacol. 2024;15:1361651. doi: 10.3389/fphar.2024.1361651.
25. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016;12(6):719–32. doi: 10.1016/j.jalz.2016.02.010.
26. Kim YG, Jeon JY, Kim HJ, Kim DJ, Lee KW, Moon SY, Han SJ. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase iv inhibitors versus sulfonylureas: A real-world population-based cohort study. J Clin Med. 2018;8(1):28. doi: 10.3390/jcm8010028. Erratum in: J Clin Med. 2019;8(3):E389. doi: 10.3390/jcm8030389.
27. Isik AT, Soysal P, Yay A, Usarel C. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. Diabetes Res Clin Pract. 2017;123:192–98. doi: 10.1016/j.diabres.2016.12.010.
28. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. 12-й выпуск. М. 2025.
29. Bohm A-K, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: Fixed-dose versus loosedose combination therapy for type 2 diabetes. PLoS ONE. 2021;16(5):e0250993. doi: 10.1371/journal.pone.0250993.
30. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинском применению лекарственного препарата Форсиглекс® Лонг. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8ceaf2b6-8a2d-4835-bc14-d8e8839fdab9 (дата обращения – 03.10.2025).
31. Kim YY, Lee JS, Kang HJ, Park SM. Eff of medication adherence on longterm all-cause-mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patients. Sci Rep. 2018;8(1):12190. doi: 10.1038/s41598-018-30740-y.
32. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–87. doi: 10.2337/dc07-0627. Erratum in: Diabetes Care. 2008;31(8):1713.
33. Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010;88(6):801–8. doi: 10.1038/clpt.2010.184. Erratum in: Clin Pharmacol Ther. 2011;89(2):320.
Review
For citations:
Demidova T.Yu., Izmailova M.Ya. New facets of the multiorgan effectiveness of dipeptidyl peptidase-4 inhibitors. FOCUS. Endocrinology. 2025;6(3):47-58. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-3-11
Views:
81
JATS XML
Email this article 